Nexalin Technology, Inc. - Common Stock (NQ:NXL)

4.180 -0.210 (-4.78%)

Streaming Delayed Price Updated: 1:00 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Volume	4,515
Open	4.500
Bid (Size)	4.010 (300)
Ask (Size)	5.000 (200)
Prev. Close	4.390
Today's Range	4.100 - 4.530
52wk Range	4.000 - 60.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

September 11, 2026

From RedChip Companies, Inc. (Media Suite)

Via ACCESS Newswire

These stocks are moving in today's session ↗

August 27, 2026

Via Chartmill

Performance

YTD	-76.1%	-76.1%
1 Month	-44.3%	-44.3%
3 Month	-59.3%	-59.3%
6 Month	-60.5%	-60.5%
1 Year	-85.3%	-85.3%

More News

Wondering what's happening in today's pre-market session? ↗

August 27, 2026

Via Chartmill

Nexalin Technology Announces Reverse Stock Split

August 27, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Tuesday? ↗

July 28, 2026

Via Chartmill

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

June 25, 2026

Via Chartmill

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform

June 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

June 16, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

June 10, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

June 04, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Discover the top movers in Friday's pre-market session. ↗

May 22, 2026

Via Chartmill

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 21, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

May 19, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

April 28, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

April 22, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

RedChip's Biotech Investor Conference Replays Now Available

April 20, 2026

Via ACCESS Newswire

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

April 15, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21

April 14, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

April 09, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

April 02, 2026

Via ACCESS Newswire

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

February 24, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

February 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 13, 2026

Via ACCESS Newswire

Unusual volume stocks in Friday's session ↗

February 06, 2026

Via Chartmill

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

February 05, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?

Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.

What exchange does Nexalin Technology, Inc. - Common Stock trade on?

Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?

The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market

What is the current price of Nexalin Technology, Inc. - Common Stock?

The current price of Nexalin Technology, Inc. - Common Stock is 4.180

When was Nexalin Technology, Inc. - Common Stock last traded?

The last trade of Nexalin Technology, Inc. - Common Stock was at 09/28/26 01:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.